Ngā hua rapu - Richard Pazdur

Whakamahine hua
  1. 1
    Endpoints for Assessing Drug Activity in Clinical Trials

    Endpoints for Assessing Drug Activity in Clinical Trials mā Richard Pazdur

    I whakaputaina 2008
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  2. 2
    Re-Evaluating Eligibility Criteria for Oncology Clinical Trials: Analysis of Investigational New Drug Applications in 2015

    Re-Evaluating Eligibility Criteria for Oncology Clinical Trials: Analysis of Investigational New Drug Applications in 2015 mā Susan Jin, Richard Pazdur, Rajeshwari Sridhara

    I whakaputaina 2017
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  3. 3
    Approval Summary: Pemetrexed in the Initial Treatment of Advanced/Metastatic Non-Small Cell Lung Cancer

    Approval Summary: Pemetrexed in the Initial Treatment of Advanced/Metastatic Non-Small Cell Lung Cancer mā Martin H. Cohen, Robert Justice, Richard Pazdur

    I whakaputaina 2009
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  4. 4
    FDA Drug Approval Summary: Alemtuzumab as Single-Agent Treatment for B-Cell Chronic Lymphocytic Leukemia

    FDA Drug Approval Summary: Alemtuzumab as Single-Agent Treatment for B-Cell Chronic Lymphocytic Leukemia mā Suzanne Demko, Jeffrey Summers, Patricia Keegan, Richard Pazdur

    I whakaputaina 2008
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  5. 5
    Rare Cancer Trial Design: Lessons from FDA Approvals

    Rare Cancer Trial Design: Lessons from FDA Approvals mā Himabindu Gaddipati, Ke Liu, Anne Pariser, Richard Pazdur

    I whakaputaina 2012
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  6. 6
    U.S. Food and Drug Administration Drug Approval Summary: Conversion of Imatinib Mesylate (STI571; Gleevec) Tablets from Accelerated Approval to Full Approval

    U.S. Food and Drug Administration Drug Approval Summary: Conversion of Imatinib Mesylate (STI571; Gleevec) Tablets from Accelerated Approval to Full Approval mā Martin H. Cohen, John R. Johnson, Richard Pazdur

    I whakaputaina 2005
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  7. 7
    FDA report: Ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease

    FDA report: Ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease mā Min Lu, Martin H. Cohen, Dwaine Rieves, Richard Pazdur

    I whakaputaina 2010
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  8. 8
    United States Food and Drug Administration Approval Summary: Bortezomib for the Treatment of Progressive Multiple Myeloma after One Prior Therapy

    United States Food and Drug Administration Approval Summary: Bortezomib for the Treatment of Progressive Multiple Myeloma after One Prior Therapy mā Robert C. Kane, Ann T. Farrell, Rajeshwari Sridhara, Richard Pazdur

    I whakaputaina 2006
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  9. 9
    FDA Drug Approval Summary: Bevacizumab plus Interferon for Advanced Renal Cell Carcinoma

    FDA Drug Approval Summary: Bevacizumab plus Interferon for Advanced Renal Cell Carcinoma mā Jeff Summers, Martin H. Cohen, Patricia Keegan, Richard Pazdur

    I whakaputaina 2010
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  10. 10
    Velcade®: U.S. FDA Approval for the Treatment of Multiple Myeloma Progressing on Prior Therapy

    Velcade®: U.S. FDA Approval for the Treatment of Multiple Myeloma Progressing on Prior Therapy mā Robert C. Kane, Peter Bross, Ann T. Farrell, Richard Pazdur

    I whakaputaina 2003
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  11. 11
    FDA Drug Approval Summary: Bevacizumab Plus FOLFOX4 as Second-Line Treatment of Colorectal Cancer

    FDA Drug Approval Summary: Bevacizumab Plus FOLFOX4 as Second-Line Treatment of Colorectal Cancer mā Martin H. Cohen, Joe Gootenberg, Patricia Keegan, Richard Pazdur

    I whakaputaina 2007
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  12. 12
    Approval Summary: Pemetrexed Maintenance Therapy of Advanced/Metastatic Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)

    Approval Summary: Pemetrexed Maintenance Therapy of Advanced/Metastatic Nonsquamous, Non-Small Cell Lung Cancer (NSCLC) mā Martin H. Cohen, Patricia Cortazar, Robert Justice, Richard Pazdur

    I whakaputaina 2010
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  13. 13
    Approval Summary: Imatinib Mesylate in the Treatment of Metastatic and/or Unresectable Malignant Gastrointestinal Stromal Tumors

    Approval Summary: Imatinib Mesylate in the Treatment of Metastatic and/or Unresectable Malignant Gastrointestinal Stromal Tumors mā Martin H. Cohen, Ann T. Farrell, Robert Justice, Richard Pazdur

    I whakaputaina 2009
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  14. 14
    FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors

    FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors mā Leigh Marcus, Steven J. Lemery, Patricia Keegan, Richard Pazdur

    I whakaputaina 2019
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  15. 15
    FDA Drug Approval Summary: Nelarabine (Arranon®) for the Treatment of T-Cell Lymphoblastic Leukemia/Lymphoma

    FDA Drug Approval Summary: Nelarabine (Arranon®) for the Treatment of T-Cell Lymphoblastic Leukemia/Lymphoma mā Martin H. Cohen, John R. Johnson, Robert Justice, Richard Pazdur

    I whakaputaina 2008
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  16. 16
    FDA Drug Approval Summary: Bevacizumab (Avastin®) as Treatment of Recurrent Glioblastoma Multiforme

    FDA Drug Approval Summary: Bevacizumab (Avastin®) as Treatment of Recurrent Glioblastoma Multiforme mā Martin H. Cohen, Yuan Li Shen, Patricia Keegan, Richard Pazdur

    I whakaputaina 2009
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  17. 17
    FDA Drug Approval Summaries: Fulvestrant

    FDA Drug Approval Summaries: Fulvestrant mā Peter Bross, Martin H. Cohen, Grant A. Williams, Richard Pazdur

    I whakaputaina 2002
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  18. 18
    Low-dose continuous infusion 5-fluorouracil. Evaluation in advanced breast carcinoma

    Low-dose continuous infusion 5-fluorouracil. Evaluation in advanced breast carcinoma mā S. Huan, Richard Pazdur, Amnuay Singhakowinta, Bohumil A. Samal, Vainutis K. Vaitkevicus

    I whakaputaina 1989
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  19. 19
    Prospective evaluation of adrenal insufficiency in patients with adrenal metastasis

    Prospective evaluation of adrenal insufficiency in patients with adrenal metastasis mā Bruce G. Redman, Richard Pazdur, Alkis P. Zingas, Rene D. Loredo

    I whakaputaina 1987
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  20. 20
    Prognostic Value of the Lung Immune Prognostic Index for Patients Treated for Metastatic Non–Small Cell Lung Cancer

    Prognostic Value of the Lung Immune Prognostic Index for Patients Treated for Metastatic Non–Small Cell Lung Cancer mā Dickran Kazandjian, Yutao Gong, Patricia Keegan, Richard Pazdur, Gideon M. Blumenthal

    I whakaputaina 2019
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:

Ngā utauta rapu: